跳至主要内容
临床试验/CTRI/2018/07/015116
CTRI/2018/07/015116Other不适用

A blood test to determine the probability of developing cancer and/ or its stage, by analysing theexpression profile of molecular immuno-markers in healthy and cancer patients.

Epigeneres Biotech Pvt Ltd1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2018年7月31日最近更新:

试验速览

阶段
不适用
状态
Other
入组人数
1,000
试验地点
1
主要终点
The expression profile of the molecular immuno-

研究概览

简要总结

The study was terminated because the protocol required some modification. Total of 24 participants were enrolled in this study.

研究设计

研究类型
Observational

入排标准

年龄范围
21.00 Year(s) 至 85.00 Year(s)(—)
性别
All

入选标准

  • Cancer group.
  • Have a type of cancer disease.
  • Healthy group.
  • who are not on any regular medication.
  • Are aged 21 years or older.
  • Are willing to consent to the storage of specimens for future research.
  • Subjects enrolled will be able to provide informed consent for themselves.

排除标准

  • Are incarcerated.
  • 2 Are unwilling or unable to comply with prescribed therapy.
  • Subjects that lack the capacity to provide informed consent autonomously are to be excluded.
  • Pregnant or lactating women.
  • Subjects who have participated in any clinical trial in the past 1 month.
  • Any other condition that in the opinion of the investigator that does not justify the subject’s participation in the trial.

结局指标

主要结局

The expression profile of the molecular immuno-

时间窗: 0 days

markers will help in analyzing the probability of manifestation of cancer, before any clinical

时间窗: 0 days

symptoms begin to appear in healthy individuals and the development of the disease in

时间窗: 0 days

cancer patients.

时间窗: 0 days

次要结局

  • The expression profile of the molecular immuno-(markers will help in understanding the efficacious treatment for the cancer patient)

研究者

申办方类型
Other [Biotechnology Company]

研究点 (1)

Loading locations...

相似试验

A blood test to detect the presence or absence of... | 临床试验